Coinbase
COIN
Salesforce
CRM
Microsoft
MSFT
Amazon
AMZN
Meta Platforms
META
US Stock MarketDetailed Quotes
BPTH Bio-Path Holdings
- 0.165
- -0.003-1.79%
15min DelayTrading Mar 11 09:31 ET
951.70KMarket Cap-0.02P/E (TTM)
0.165High0.165Low324Volume0.165Open0.168Pre Close53.46Turnover0.01%Turnover Ratio0.00P/E (Static)5.77MShares7.67052wk High-1.34P/B887.12KFloat Cap0.12152wk Low--Dividend TTM5.38MShs Float23999.988Historical High--Div YieldTTM0.00%Amplitude0.121Historical Low0.165Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Bio-Path Holdings Stock Forum
#pleaseDontScareMe
Bio-Path Holdings Expands Global Patent Portfolio
Thursday, 13th February at 4:01 pm
HOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced the receipt of newly issued patents in the United States and New Zealand, and updated investors on th...
Breakthrough Cancer Trial Results: Bio-Path's Dual Success in Solid Tumors and AML Remission
No comment yet